Intrarosa carries a cash price of roughly $320 for a 28-day supply, putting it in the same tier as brand-name vaginal estrogen creams. The price surprises many people because its active ingredient, DHEA, is a naturally occurring hormone that can be purchased over the counter as an oral supplement for a fraction of the cost. Several factors drive the high price, from its unique regulatory position to the business realities of a niche pharmaceutical product with no generic competition.
What Makes Intrarosa Different
Intrarosa is a synthetic form of DHEA delivered as a daily vaginal insert to treat painful sex caused by menopause-related vaginal changes. What sets it apart from vaginal estrogen creams and tablets is how it works: DHEA itself has no estrogenic or androgenic activity. Instead, cells in the vaginal lining convert it locally into both estrogen and androgens, which act on the tissue without meaningfully raising hormone levels elsewhere in the body.
This distinction matters most for people who cannot use estrogen. All estrogen-based vaginal products, even low-dose local ones, carry a black box warning for risks including cardiovascular disease and certain cancers. Intrarosa does not carry that same warning. For women with a history of breast cancer, other estrogen-sensitive cancers, or significant cardiovascular risk, Intrarosa may be one of the only FDA-approved prescription options available. That narrow but important patient population gives the manufacturer pricing leverage: when there’s no direct substitute, the drug can command a premium.
No Generic and Limited Competition
Intrarosa has no generic equivalent on the market. It is the only FDA-approved vaginal DHEA product, which means there is no price competition from identical formulations. Vaginal estrogen products like estradiol cream exist in both brand and generic forms, but they are not interchangeable with Intrarosa because they contain different active ingredients and carry different safety profiles. Without a generic competitor to push the price down, the manufacturer can set whatever the market will bear.
The drug’s rights were sold in 2020 by AMAG Pharmaceuticals to Millicent Pharma, a company backed by the private equity firm The Carlyle Group, in a deal worth up to $125 million. When a private equity-backed company pays that kind of acquisition price for a single product, recouping that investment through drug revenue becomes a central business objective, which works against any incentive to lower the sticker price.
The Cost Isn’t Much Higher Than Alternatives
Here’s what surprises some people: Intrarosa’s cash price is actually comparable to, or even slightly lower than, some brand-name vaginal estrogen products. A 28-day supply of Intrarosa runs about $322 without insurance, while a tube of brand-name Estrace vaginal cream costs around $345. The problem isn’t that Intrarosa is dramatically more expensive than its competitors. The problem is that the entire category of brand-name vaginal hormone treatments is expensive, and insurance coverage varies widely.
If your insurance covers one of these products but not the others, the out-of-pocket difference can be enormous. Many insurers prefer to cover older, generic estrogen options first and require prior authorization for Intrarosa. If you’re paying cash because your plan doesn’t cover it, you’re absorbing a price designed with insurer reimbursement in mind.
Why the Daily Dosing Adds Up
Intrarosa is used once daily, every day. Most vaginal estrogen products, by contrast, are prescribed at a maintenance dose of twice per week after an initial loading period. That difference in dosing frequency means you go through Intrarosa supplies faster and refill more often. Even if the per-unit cost were identical, the daily schedule would make Intrarosa more expensive on an annual basis simply because you’re using more of it.
Compounded DHEA as a Cheaper Alternative
Some compounding pharmacies prepare vaginal DHEA suppositories at a significantly lower cost than Intrarosa. These are custom-made by a pharmacist rather than manufactured in an FDA-regulated facility. Compounded DHEA suppositories can cost a fraction of the branded product’s price, which is why many clinicians mention them as an option.
The trade-off is consistency and oversight. Compounded products are not subject to the same FDA quality controls that govern manufactured drugs. There is no guarantee that each suppository contains exactly the labeled dose, and the formulations are not tested in clinical trials the way Intrarosa was. For some people, the cost savings are worth that trade-off. For others, especially those whose doctors specifically recommended an FDA-approved product, it may not be.
Does the Price Reflect Added Clinical Value?
Independent drug reviews have been blunt on this point. A Canadian health technology assessment found insufficient evidence that Intrarosa provides any clinical benefit over existing vaginal estrogen therapies. The review concluded there is “no evidence to support a price premium” compared to other treatments for the same condition. Intrarosa’s unique value is its safety profile for estrogen-averse patients, not superior effectiveness for the general population.
If you can safely use vaginal estrogen, a generic estradiol cream or tablet will likely cost less and work just as well. Intrarosa’s price is most justifiable for people who specifically need a non-estrogen option, where the alternatives are either compounded products or no treatment at all. In that context, the cost reflects the reality of a specialty drug serving a smaller market with no competition, not a product that outperforms cheaper options.